In fact, the ROCK family, including ROCK1 and ROCK2, has recently attracted interest as a potential therapeutic target for the treatment of metabolic disorders, based upon the fact that upregulated ROCK activity is involved in the pathogenesis of nearly all of the metabolic syndromes including obesity, insulin resistance, dyslipidemia and hypertension [16]. This evidence concerns the gene ROCK1 and metabolic syndrome.